Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Getting To $80 Bil.: PhRMA Expects Mix Of Drug Rebates And Fees In Senate Finance Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

In addition to the announced discount for drugs in the Part D donut hole, PhRMA anticipates the Senate Finance Committee's bipartisan bill will seek rebates and fees from pharmaceutical manufacturers.

You may also be interested in...

House Health Reform Bill Nets $48 Bil. From Pharma - CBO

The Congressional Budget Office has put a value on the net savings that would accrue to the federal government through drug rebate and discount provisions in the pending House health care reform bill: $48 billion over 10 years

PhRMA Donut Hole Pledge Sets Nice Tone, But Negotiations Continue On $80 Bil. Contribution

Higher drug rebates to Medicaid, Medicare under discussion, as are savings from follow-on biologics.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts